News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Generic medicines news

Show

From To
Generic HIV drugs will be a good thing right?

It is an open question whether generic competition in the United States, at least in the short term, will actually materialize or if it does, lead to reduced prices. If savings are realized, there is also no guarantee they will be funneled back into other critical HIV services.

Published
27 October 2016
From
Project Inform
PrEP
Tests of online PrEP purchases by London clinic find no fakes, and adequate drug levels

A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate

Published
26 October 2016
By
Gus Cairns
Access to medicines and treatment
New $90-$90-$90 target needed for global viral hepatitis, HIV and TB treatment

The costs of making drugs to treat viral hepatitis, HIV and tuberculosis (TB) are now so low that each disease could be treated for less than

Published
24 October 2016
By
Keith Alcorn
PrEP
Dutch model finds PrEP for high-risk gay men is cost-effective at current prices and cost-saving at generic prices

A mathematical modelling study based on the HIV epidemic in the Netherlands has found that daily pre-exposure prophylaxis (PrEP) would be cost-effective even at current drug prices

Published
27 September 2016
By
Gus Cairns
Pharmaceutical industry
CHMP Recommends for Approval Generic Version of Truvada

At its September meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Truvada – Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine/tenofovir disoproxil) for the treatment of HIV infection.

Published
20 September 2016
From
EATG
Hepatitis C treatment
WHO Issues Guideline For Manufacturers Of Generic Hepatitis C Medicine

The World Health Organization has issued a guidance document on the design of bioequivalence studies for a leading hepatitis C medicine. Generic drug companies seeking prequalification by the WHO need to demonstrate that their generic version is equivalent to the originator drug.

Published
08 April 2015
From
Intellectual Property Watch
PrEP policies and guidelines
When Might Generic Truvada Be Available for PrEP in the US?

Our best guess is that generic Truvada could be available in December 2017, initially produced by Teva, a major generic producer. Two other generic companies, Lupin Pharmaceuticals and Cipla may follow soon after creating competition that can really bring prices down.

Published
17 March 2015
From
Ethan The Blog
Generic medicines
Generic antiretrovirals could save NHS £1.25 billion over 5 years, study finds

Switching all patients taking antiretrovirals in the United Kingdom to generic versions of the drugs they are taking, if available, would save around £1.25 billion between 2015 and

Published
04 November 2014
By
Michael Carter
Generic medicines
Preparing for Generics: The push for affordable HIV treatment doesn’t end with patent expirations

The United States is on course for some much-needed economic relief from the crippling cost of HIV treatment, with the anticipated arrival of generic versions of guidelines- preferred antiretrovirals. However, much preparation is required to maximize price competition, maintain patient choice, and ensure that savings are used to the advantage of people living with HIV.

Published
11 April 2013
From
Treatment Action Group
Access to medicines and treatment
Athens urged to import generic drugs

Public health advocates are petitioning the Greek government to overturn patent protection on costly medicines and import them from low-cost generic producers to ease the burden on the country’s medical system.

Published
18 March 2013
From
Financial Times
← Prev1...23456Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.